Science 37 (SNCE) to Release Quarterly Earnings on Thursday

Posted by MarketBeat News on Aug 4th, 2022

Science 37 (NASDAQ:SNCE – Get Rating) is set to announce its earnings results before the market opens on Thursday, August 11th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Science 37 has set its FY 2022 guidance at EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

Science 37 (NASDAQ:SNCE – Get Rating) last issued its quarterly earnings results on Monday, May 9th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. The business had revenue of $18.69 million for the quarter, compared to analyst estimates of $27.00 million. On average, analysts expect Science 37 to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Science 37 Trading Up 3.9 %

Shares of NASDAQ:SNCE opened at $2.38 on Thursday. The firm has a fifty day moving average price of $2.66 and a 200 day moving average price of $4.74. Science 37 has a 1-year low of $1.61 and a 1-year high of $15.10.

Institutional Trading of Science 37

Several hedge funds and other institutional investors have recently made changes to their positions in SNCE. Citigroup Inc. purchased a new position in Science 37 during the 1st quarter valued at about $37,000. Virtu Financial LLC purchased a new position in Science 37 during the 1st quarter valued at about $60,000. JPMorgan Chase & Co. increased its holdings in Science 37 by 29.0% during the 1st quarter. JPMorgan Chase & Co. now owns 14,574 shares of the company’s stock valued at $78,000 after acquiring an additional 3,272 shares in the last quarter. Shay Capital LLC purchased a new position in Science 37 during the 1st quarter valued at about $120,000. Finally, Bank of America Corp DE purchased a new position in Science 37 during the 1st quarter valued at about $167,000. Institutional investors and hedge funds own 46.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on SNCE shares. Craig Hallum began coverage on shares of Science 37 in a research note on Tuesday, June 7th. They set a “buy” rating and a $10.00 price target for the company. Robert W. Baird restated a “buy” rating and issued a $12.00 target price on shares of Science 37 in a research note on Friday, April 8th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $14.00.

Science 37 Company Profile

(Get Rating)

Science 37 Holdings, Inc provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data.